{"id":"elv-cobi-ftc-taf","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Elevated creatinine"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ELV/COBI/FTC/TAF combines an integrase strand transfer inhibitor (elvitegravir), a pharmacokinetic booster (cobicistat), and two nucleoside/nucleotide reverse transcriptase inhibitors (emtricitabine and tenofovir alafenamide). This multi-mechanism approach targets different steps of the HIV replication cycle, reducing viral load and preventing resistance development. The cobicistat component enhances the bioavailability of elvitegravir and tenofovir alafenamide, allowing for lower doses and improved tolerability.","oneSentence":"This is a fixed-dose combination of four antiretroviral agents that work together to suppress HIV replication through multiple mechanisms: elvitegravir inhibits integrase, cobicistat boosts drug levels, and emtricitabine and tenofovir alafenamide inhibit reverse transcriptase.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:45:19.742Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced adults"}]},"trialDetails":[{"nctId":"NCT03067285","phase":"PHASE4","title":"A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2017-09-08","conditions":"HIV Infections","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ELV/COBI/FTC/TAF","genericName":"ELV/COBI/FTC/TAF","companyName":"Fundacion SEIMC-GESIDA","companyId":"fundacion-seimc-gesida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a fixed-dose combination of four antiretroviral agents that work together to suppress HIV replication through multiple mechanisms: elvitegravir inhibits integrase, cobicistat boosts drug levels, and emtricitabine and tenofovir alafenamide inhibit reverse transcriptase. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}